STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation		
Title and abstract	1	(a) Indicate the study's design with a commonly used term in	1	
		the title or the abstract		
		(b) Provide in the abstract an informative and balanced	3-4	
		summary of what was done and what was found		
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the	5-7	
		investigation being reported		
Objectives	3	State specific objectives, including any prespecified hypotheses	7	
Methods				
Study design	4	Present key elements of study design early in the paper	7-8	
Setting	5	Describe the setting, locations, and relevant dates, including	9-10	
-		periods of recruitment, exposure, follow-up, and data collection		
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	9-10	
·		selection of participants. Describe methods of follow-up		
		(b) For matched studies, give matching criteria and number of	N/A	
		exposed and unexposed	,	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	11-12	
		confounders, and effect modifiers. Give diagnostic criteria, if		
		applicable		
Data sources/	8*	For each variable of interest, give sources of data and details of	11-12	
measurement		methods of assessment (measurement). Describe comparability		
		of assessment methods if there is more than one group		
Bias	9	Describe any efforts to address potential sources of bias	8-9	
Study size	10	Explain how the study size was arrived at	N/A	
Quantitative	11	Explain how quantitative variables were handled in the	11-12	
variables		analyses. If applicable, describe which groupings were chosen		
		and why		
Statistical methods	12	(a) Describe all statistical methods, including those used to	11	
		control for confounding		
		(b) Describe any methods used to examine subgroups and	10-12	
		interactions		
		(c) Explain how missing data were addressed	N/A	
		(d) If applicable, explain how loss to follow-up was addressed	N/A	
		(<u>e</u>) Describe any sensitivity analyses	10	
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	12	
		numbers potentially eligible, examined for eligibility, confirmed		
		eligible, included in the study, completing follow-up, and		
		analysed		
		(b) Give reasons for non-participation at each stage	N/A	
		(c) Consider use of a flow diagram	N/A	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	Tables	
		clinical, social) and information on exposures and potential		
		confounders		

variab	٦	٥f	into	roct
variab	ıe	OI	mte	rest

		(c) Summarise follow-up time (eg, average and total amount)	N/A
Outcome data	15*	Report numbers of outcome events or summary measures over	Tables 2/3
		time	13-14
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	Table 2
		adjusted estimates and their precision (eg, 95% confidence	Table 3
		interval). Make clear which confounders were adjusted for and	
		why they were included	
		(b) Report category boundaries when continuous variables were	Table 2
		categorized	Table 3
		(c) If relevant, consider translating estimates of relative risk into	N/A
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	14-15
		interactions, and sensitivity analyses	Supplements
Discussion			
Key results	18	Summarise key results with reference to study objectives	15-16
Limitations	19	Discuss limitations of the study, taking into account sources of	16-17
		potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	18
		objectives, limitations, multiplicity of analyses, results from	
		similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study	17-18
		results	
Other information			
Funding	22	Give the source of funding and the role of the funders for the	2
		present study and, if applicable, for the original study on which	
		the present article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

Citation:

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008 Apr;61(4):344-9. PMID: 18313558